2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
9
Breast Neoplasms
6
Lymphoma, B-Cell, Marginal Zone
4
Barrett Esophagus
4
Lymphoma, Large B-Cell, Diffuse
3
Inflammation
3
Head and Neck Neoplasms
3
Zollinger-Ellison Syndrome
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Lymphoma
2
Colorectal Neoplasms
2
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Stomach Ulcer
1
Solid Tumours
1
Solid Tumor
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Patients
1
Precancerous Gastric Lesions
1
Pharmacokinetics of MDV3100
1
Peripheral Nervous System Diseases
1
Ovarian Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
enzalutamide
20
Abiraterone Acetate
11
Prednisone
7
Docetaxel
7
radium Ra 223 dichloride
6
darolutamide
5
abiraterone
5
apalutamide
3
olaparib
2
niraparib
2
cabazitaxel
2
atezolizumab
2
Pluvicto
2
Nivolumab
2
zimberelimab
1
xentuzumab
1
tasquinimod
1
sacituzumab govitecan
1
sabizabulin
1
quemliclustat
1
pembrolizumab
1
ipatasertib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
TVB-2640
1
Standard of Care
1
Rosuvastatin Calcium
1
Radium-223
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
Omeprazole
×
Clear all
NCT04337580
2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2
Recruiting
50 enrolled